Cited by 43Metabolism, Diabetes, and CancerDiet, Metabolism, and DiseaseLipid metabolism and disorders

PPP2R5C couples hepatic glucose and lipid homeostasis

Open access
Cheng, Yong-Sheng, Seibert, Oksana, Klöting, Nora, Dietrich, Arne, Straßburger, Katrin, Fernández-Veledo, Sonia, Vendrell, Joan J., Zorzano, Antonio +4 more·2015·PLoS Genetics

Abstract

In mammals, the liver plays a central role in maintaining carbohydrate and lipid homeostasis by acting both as a major source and a major sink of glucose and lipids. In particular, when dietary carbohydrates are in excess, the liver converts them to lipids via de novo lipogenesis. The molecular checkpoints regulating the balance between carbohydrate and lipid homeostasis, however, are not fully understood. Here we identify PPP2R5C, a regulatory subunit of PP2A, as a novel modulator of liver metabolism in postprandial physiology. Inactivation of PPP2R5C in isolated hepatocytes leads to increased glucose uptake and increased de novo lipogenesis. These phenotypes are reiterated in vivo, where hepatocyte specific PPP2R5C knockdown yields mice with improved systemic glucose tolerance and insulin sensitivity, but elevated circulating triglyceride levels. We show that modulation of PPP2R5C levels leads to alterations in AMPK and SREBP-1 activity. We find that hepatic levels of PPP2R5C are elevated in human diabetic patients, and correlate with obesity and insulin resistance in these subjects. In sum, our data suggest that hepatic PPP2R5C represents an important factor in the functional wiring of energy metabolism and the maintenance of a metabolically healthy state.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pgen.1005561

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Hepatocyte-specific B56γ knockdown reduced B56γ mRNA by 85% and protein by 50% in the liver.

    “These mice showed a significant reduction in B56γ mRNA (85%) and protein (50%) levels in the liver.”
  • This phenotype was not caused by effects on gluconeogenesis or insulin-induced AKT or GSK-3β phosphorylation, but rather by increased glucose uptake by hepatocytes.

    “this phenotype was not caused by any effects on gluconeogenesis or insulin-induced AKT or GSK-3β phosphorylation, but rather by increased glucose uptake by the hepatocytes.”
  • B56γ knockdown livers had increased triglyceride levels, suggesting increased de novo lipogenesis.

    “increased triglyceride levels were found in the B56γ KD livers, suggestive for increased de novo lipogenesis.”
  • BIO-ID and PLA assays revealed a role for PP2A-B56γ in directly controlling AMPK activity, with enhanced Thr172 phosphorylation in B56γ knockdown livers, and in suppressing HIF1α transcriptional activity.

    “BIO-ID and PLA assays revealed a role for PP2A-B56γ in the direct control of AMP-activated protein Kinase (AMPK) activity (Thr172 phosphorylation was enhanced in the B56γ KD livers) and in the suppression of Hypoxia Inducible Factor 1α (HIF1α) transcriptional activity.”
  • In livers of type 2 diabetic patients, PPP2R5C expression was significantly increased, and visceral obesity correlated with PPP2R5C transcription in non-diabetic patients.

    “in livers of type 2 diabetic patients, PPP2R5C expression was significantly increased, and visceral obesity correlated with PPP2R5C transcription in non-diabetic patients [73].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Cheng, Y.-S., Seibert, O., Klöting, N., Dietrich, A., Straßburger, K., Fernández-Veledo, S., Vendrell, J. J., Zorzano, A., Blüher, M., Herzig, S., Berriel Diaz, M., & Teleman, A. A.
Affiliations
  • German Cancer Research Center (DE)
  • Leipzig University (DE)
  • Institut de Recerca Biomèdica Catalunya Sud (ES)
Corresponding author
Teleman, Aurelio A.
Venue
PLoS Genetics
Published
2015-10-06
Volume
11
Issue
10
Pages
e1005561
ISSN
  • 1553-7390 (ISSN-L)
  • 1553-7404
OpenAlex
W2259447096
Cited by
43
References
53
Citations by year
2026: 2 · 2025: 4 · 2024: 1 · 2023: 4 · 2022: 4 · 2021: 1 · 2020: 5 · 2019: 5 · 2018: 3 · 2017: 4 · 2016: 9
FWCI
2.32
Type
journal article
Language
en
Open access
Locations
  • PLoS Genetics (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (publishedVersion, cc-by)
  • RECERCAT (Consorci de Serveis Universitaris de Catalunya) (publishedVersion, other-oa)
  • Rovira & Virgili repository (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • Site cant be reached (submittedVersion, cc-by)
  • PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion, cc-by)
Funders
  • Deutsches Krebsforschungszentrum
  • Deutsche Forschungsgemeinschaft (SFB1118)
  • Ministerio de Economía y Competitividad (SAF2012, SAF2012-36186)
  • Fritz Thyssen Stiftung
  • Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (CP10/00438, CB07708/0012)
  • Instituto de Salud Carlos III (CP10/ 00438, CB07708/0012)
  • European Regional Development Fund (SAF2012-36186, CP10/00438, CB07708/0012)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords
PPP2R5C, PP2A regulatory subunit, hepatic glucose homeostasis, hepatic lipid homeostasis, de novo lipogenesis, glucose uptake, postprandial metabolism, glucose tolerance, insulin sensitivity, triglycerides, AMPK, SREBP1, insulin resistance, obesity, diabetes mellitus, hepatocytes
MeSH terms
Animals, Dietary Carbohydrates, Energy Metabolism, Glucose, Humans, Insulin Resistance, Liver, Obesity, Hepatocytes, Lipogenesis, Lipid Metabolism, Mice, Sterol Regulatory Element Binding Protein 1, Protein Phosphatase 2, AMP-Activated Protein Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review